Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

Yannick Arlot-Bonnemains1, Enke Baldini, Benedicte Martin

  • 1CNRS-UMR 6061 Génétique et Développement, IFR 140 GFAS, Faculté de Médecine, Université Rennes 1, 35043 Rennes Cedex, France.

Insights

VX-680, an Aurora kinase inhibitor, effectively reduces anaplastic thyroid cancer (ATC) cell growth by inhibiting proliferation and inducing apoptosis. This study highlights VX-680

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor prognosis.
  • ATC cells exhibit cell cycle dysregulation, uncontrolled proliferation, and genomic instability.
  • Current treatments for ATC have limited efficacy.

Purpose of the Study:

  • To evaluate the in vitro efficacy of VX-680, an Aurora kinase inhibitor, against anaplastic thyroid cancer cells.
  • To assess the effects of VX-680 on ATC cell proliferation, apoptosis, colony formation, cell cycle, and ploidy.

Main Methods:

  • VX-680 treatment of ATC cell lines (CAL-62, 8305C, 8505C, BHT-101).
  • Assays for proliferation, apoptosis (caspase-3 activity), soft agar colony formation, cell cycle analysis, and ploidy.
  • Time-lapse microscopy and histone H3 phosphorylation analysis.

Main Results:

  • VX-680 inhibited ATC cell proliferation in a dose- and time-dependent manner (IC50: 25-150 nM).
  • VX-680 significantly reduced soft agar colony formation and induced apoptosis.
  • VX-680 treatment led to polyploidy (cells with >4N DNA content) and aberrant cell division, abrogating histone H3 phosphorylation.

Conclusions:

  • VX-680 demonstrates significant in vitro anti-cancer activity against multiple ATC cell lines.
  • VX-680's mechanism involves cell cycle disruption, leading to proliferation inhibition and apoptosis.
  • VX-680 shows therapeutic potential for anaplastic thyroid cancer treatment, warranting further investigation.